In this study hemodialysis patients that underwent dialysis thrice weekly screen for uremic
pruritus and 80 patients that at least have refractive pruritus that lead to sleep and daily
activity disorders enroll in this study. These patients should have at least a course of
therapy without proper response. After proper informing patients and taking testimonial
patients enter to study. Then patients randomized in case and control group. In case group,
patients took montelukast 10 milligram daily and in control group took placebo for 30 days.
Other antipruritic or antiinflammatory medication has been stopped one week prior to starting
treatment. Calcium, phosphorous, urea, creatinine, highly sensitive CRP (hsCRP), Parathyroid
Hormone (PTH), hemoglobin and kt/V were measured at beginning and at end of study. pruritus
severity assessed by Detailed Pruritus Score that introduced by Duo and Visual Analogue Score
in beginning and at end of study in both group. Sleep disorder score and its severity added
to crude score at beginning and end of study and change of measures analyzed.